PDF
Full
Outline
To explore the safety and efficacy of Inetetamab combined with Pyrotinib in the treatment of HER2-positive breast cancer.
A case of patient was reported with right breast invasive ductal carcinoma with multiple systemic metastases. The patients were found progressing after 3 cycles of docetaxel+Capecitabine+Trastuzumab regimen as the first line therapy for Trastuzumab primary resistance. Second-line therapy combined inetetamab with pyrotinib (inetetamab 8 mg·kg-1 for the first time, followed by 6 mg·kg-1, q3w+pyrotinib 400 mg·d-1, qd+vinorelbine 35 mg day 1, day 8 q3w) for 18 cycles.
The patients achieved partial response (PR) at the first evaluation. During the 18 cycles of treatment, the efficacy was evaluated as continuous PR. The current progress free survival (PFS) was more than 16 months. No grade III or above adverse reactions occurred during the treatment, and the patients were well tolerated.
The combination of inetetamab with pyrotinib is effective and safe in the treatment of metastatic HER2-positive breast cancer.
PDF
40
16
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
